The chemical biology of immunophilin ligands

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5355-5379

  Gaali, S ^a   Gopalakrishnan, R ^a   Wang, Y ^a   Kozany, C ^a   Hausch, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Chemical dimerizers; Cyclosporin; FK506; Immunosupressant; Rapamycin

Indexed keywords

ALISPORIVIR; ASCOMYCIN; CALCINEURIN; CYCLOSPORIN A; EVEROLIMUS; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROIMMUNOPHILIN; PROMUS; RAPAMYCIN; SANGLIFEHRIN A; SUNITINIB; TACROLIMUS; TEMSIROLIMUS; TIMCODAR; UNCLASSIFIED DRUG; VOCLOSPORIN; XIENC; ZOTAROLIMUS;

AFFECTIVE PSYCHOSIS; ALZHEIMER DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DRUG ELUTING STENT; HUMAN; HUNTINGTON CHOREA; HYPERBILIRUBINEMIA; KIDNEY ALLOGRAFT REJECTION; KIDNEY CANCER; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PARKINSON DISEASE; PROTEIN STABILITY; REVIEW;

EID: 82255169263     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194342     Document Type: Review

References (279)

1. Wang, X. J.; Etzkorn, F. A., Peptidyl-prolyl isomerase inhibitors. Biopolymers 2006, 84(2), 125-46.
2. Babine, R. E.; Villafranca, J. E.; Gold, B. G., FKBP immunophilin patents for neurological disorders. Expert Opin Ther. Patents 2005, 15(5), 555-573. (Pubitemid 40711761)
3. Lu, K. P.; Zhou, X. Z., The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007, 8(11), 904-16. (Pubitemid 47622559)
4. Liu, J.; Farmer, J. D., Jr.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66(4), 807-15. (Pubitemid 121001714)
5. 2+-calcineurin- NFAT signaling. Cell 2009, 138(1), 210, 210 e1.
6. Xu, X.; Su, B.; Barndt, R. J.; Chen, H.; Xin, H.; Yan, G.; Chen, L.; Cheng, D.; Heitman, J.; Zhuang, Y.; Fleischer, S.; Shou, W., FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation 2002, 73(11), 1835-8. (Pubitemid 34655263)
7. Weiwad, M.; Edlich, F.; Kilka, S.; Erdmann, F.; Jarczowski, F.; Dorn, M.; Moutty, M. C.; Fischer, G., Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006, 45(51), 15776-84. (Pubitemid 46032498)
8. Soulard, A.; Hall, M. N., SnapShot: mTOR signaling. Cell 2007, 129(2), 434.
9. Laplante, M.; Sabatini, D. M., An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009, 19(22), R1046-52.
10. Zoncu, R.; Efeyan, A.; Sabatini, D. M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12(1), 21-35.
11. Dowling, R. J. O.; Topisirovic, I.; Fonseca, B. D.; Sonenberg, N., Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 2010, 1804(3), 433-439.
12. Choo, A. Y.; Blenis, J., Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009, 8(4), 567-72.
13. Janes, M. R.; Limon, J. J.; So, L.; Chen, J.; Lim, R. J.; Chavez, M. A.; Vu, C.; Lilly, M. B.; Mallya, S.; Ong, S. T.; Konopleva, M.; Martin, M. B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D. A., Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010, 16(2), 205-13.
14. Nyfeler, B.; Bergman, P.; Triantafellow, E.; Wilson, C. J.; Zhu, Y.; Radetich, B.; Finan, P. M.; Klionsky, D. J.; Murphy, L. O., Relieving autophagy and 4EBP1 from rapamycin resistance. Mol Cell Biol 2011.
15. Zeng, Z.; Sarbassov dos, D.; Samudio, I. J.; Yee, K. W.; Munsell, M. F.; Ellen Jackson, C.; Giles, F. J.; Sabatini, D. M.; Andreeff, M.; Konopleva, M., Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109(8), 3509-12. (Pubitemid 46572543)
16. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. L.; Sabatini, D. M., Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22(2), 159-68.
17. Shor, B.; Zhang, W.-G.; Toral-Barza, L.; Lucas, J.; Abraham, R. T.; Gibbons, J. J.; Yu, K., A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis. Cancer Research 2008, 68(8), 2934-2943. (Pubitemid 351556294)
18. Powell, J. D.; Delgoffe, G. M., The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism. Immunity 2010, 33(3), 301-311.
19. Janes, M. R.; Fruman, D. A., Immune regulation by rapamycin: moving beyond T cells. Sci Signal 2009, 2(67), pe25.
20. Säemann, M. D.; Haidinger, M.; Hecking, M.; Hörl, W. H.; Weichhart, T., The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity. American Journal of Transplantation 2009, 9(12), 2655-2661.
21. Thomson, A. W.; Turnquist, H. R.; Raimondi, G., Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9(5), 324-37.
22. Araki, K.; Youngblood, B.; Ahmed, R., The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010, 235(1), 234-43.
23. Peter, C.; Waldmann, H.; Cobbold, S. P., mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol 2010, 22(5), 655-61.
24. Tresoldi, E.; DellAlbani, I.; Stabilini, A.; Jofra, T.; Valle, A.; Gagliani, N.; Bondanza, A.; Roncarolo, M. G.; Battaglia, M., Stability of human rapamyc in-expanded CD4+CD25+ T regulatory cells. Haematologica 2011, haematol.2011.041483.
25. Harrison, D. E.; Strong, R.; Sharp, Z. D.; Nelson, J. F.; Astle, C. M.; Flurkey, K.; Nadon, N. L.; Wilkinson, J. E.; Frenkel, K.; Carter, C. S.; Pahor, M.; Javors, M. A.; Fernandez, E.; Miller, R. A., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460(7253), 392-5.
26. Chen, C.; Liu, Y.; Liu, Y.; Zheng, P., mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009, 2(98), ra75.
27. Kaeberlein, M.; Kennedy, B. K., Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell 2010, 10(2), 185-90.
28. Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J. E.; Luo, S.; Oroz, L. G.; Scaravilli, F.; Easton, D. F.; Duden, R.; O'Kane, C. J.; Rubinsztein, D. C., Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36(6), 585-95. (Pubitemid 38715985)
29. Caccamo, A.; Majumder, S.; Richardson, A.; Strong, R.; Oddo, S., Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010, 285(17), 13107-20.
30. Malagelada, C.; Jin, Z. H.; Jackson-Lewis, V.; Przedborski, S.; Greene, L. A., Rapamycin Protects against Neuron Death in In vitro and In Vivo Models of Parkinson's Disease. J. Neurosci. 2010, 30(3), 1166-1175.
31. Spilman, P.; Podlutskaya, N.; Hart, M. J.; Debnath, J.; Gorostiza, O.; Bredesen, D.; Richardson, A.; Strong, R.; Galvan, V., Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5(4), e9979.
32. Santini, E.; Heiman, M.; Greengard, P.; Valjent, E.; Fisone, G., Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2009, 2(80), ra36.
33. Cirstea, D.; Hideshima, T.; Rodig, S.; Santo, L.; Pozzi, S.; Vallet, S.; Ikeda, H.; Perrone, G.; Gorgun, G.; Patel, K.; Desai, N.; Sportelli, P.; Kapoor, S.; Vali, S.; Mukherjee, S.; Munshi, N. C.; Anderson, K. C.; Raje, N., Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamyc in and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010, 9(4), 963-75.
34. Gu, J.; Ruppen, M. E.; Cai, P., Lipase-Catalyzed Regioselective Ester ification of Rapamycin: Synthesis of Temsirolimus (CCI-779). Org. Lett. 2005, 7(18), 3945-3948. (Pubitemid 41305680)
35. Claessen, B. E.; Henriques, J. P.; Dangas, G. D., Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems. Curr Pharm Des 2010, 16(36), 4012-24.
36. Kirtane, A. J.; Leon, M. B., Clinical Use of Sirolimus-Eluting Stents. Cardiovascular Drug Reviews 2007, 25(4), 316-332. (Pubitemid 350237624)
37. Wagner, R.; Mollison, K. W.; Liu, L.; Henry, C. L.; Rosenberg, T. A.; Bamaung, N.; Tu, N.; Wiedeman, P. E.; Or, Y.; Luly, J. R., Rapamycin analogs with reduced systemic exposure. Bioorganic & Medicinal Chemistry Letters 2005, 15(23), 5340-5343. (Pubitemid 41463677)
38. Fujitani, Y.; Trifilieff, A., In vivo and In vitro Effects of SAR 943, a Rapamycin Analogue, on Airway Inflammation and Remodeling. Am. J. Respir. Crit. Care Med. 2003, 167(2), 193-198. (Pubitemid 36076079)
39. Strom, T.; Shokati, T.; Klawitter, J.; Klawitter, J.; Hoffman, K.; Schiebel, H.-M.; Christians, U., Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. Journal of Mass Spectrometry 2011, 46(7), 615-624.
40. Morisaki, M.; Arai, T, Identity of immunosuppressant FR-900520 with ascomycin. J Antibiot (Tokyo) 1992, 45(1), 126-8.
41. Gollnick, H.; Kaufmann, R.; Stough, D.; Heikkila, H.; Andriano, K.; Grinienko, A.; Jimenez, P., Pimecrolimus cream 1 % in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008, 158(5), 1083-93. (Pubitemid 351521448)
42. Sedrani, R.; Kallen, J. R.; Martin Cabrejas, L. M.; Papageorgiou, C. D.; Senia, F.; Rohrbach, S.; Wagner, D.; Thai, B.; Jutzi Eme, A.-M.; France, J.; Oberer, L.; Rihs, G.; Zenke, G.; Wagner, J. r., Sanglifehrin â" Cy clophilin Interaction:â Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure, and Binding Data. Journal of the American Chemical Society 2003, 125(13), 3849-3859. (Pubitemid 36512375)
43. Gaither, L. A.; Borawski, J.; Anderson, L. J.; Balabanis, K. A.; Devay, P.; Joberty, G.; Rau, C.; Schirle, M.; Bouwmeester, T.; Mickanin, C.; Zhao, S.; Vickers, C.; Lee, L.; Deng, G.; Baryza, J.; Fujimoto, R. A.; Lin, K.; Compton, T.; Wiedmann, B., Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 2009, 397(1), 43-55.
44. Immecke, S. N; Baal, N.; Wilhelm, J.; Bechtel, J.; Knoche, A.; Bein, G.; Hackstein, H., The cyclophilin-binding agent Sanglifehrin A is a dendritic cell chemokine and migration inhibitor. PLoS One 2011, 6(3), e18406.
45. Kuglstatter, A.; Mueller, F.; Kusznir, E.; Gsell, B.; Stihle, M.; Thoma, R.; Benz, J.; Aspeslet, L.; Freitag, D.; Hennig, M., Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallographica Section D 67(2), 119-123.
46. Brittain, D. E.; Griffiths-Jones, C. M.; Linder, M. R.; Smith, M. D.; McCusker, C.; Barlow, J. S.; Akiyama, R.; Yasuda, K.; Ley, S. V., Total synthesis of antascomicin B. Angew Chem Int Ed Engl 2005, 44(18), 2732-7. (Pubitemid 40689574)
47. Ley, S. V.; Tackett, M. N.; Maddess, M. L.; Anderson, J. C.; Brennan, P. E.; Cappi, M. W.; Heer, J. P.; Helgen, C.; Kori, M.; Kouklovsky, C.; Marsden, S. P.; Norman, J.; Osborn, D. P.; Palomero, M. Á.; Pavey, J. B. J.; Pinel, C.; Robinson, L. A.; Schnaubelt, J.; Scott, J. S.; Spilling, C. D.; Watanabe, H.; Wesson, K. E.; Willis, M. C., Total Synthesis of Rapamycin. Chemistry - A European Journal 2009, 15(12), 2874-2914.
48. Sun, Y.; Hong, H.; Samborskyy, M.; Mironenko, T.; Leadlay, P. F.; Haydock, S. F., Organization of the biosynthetic gene cluster in Streptomyces sp. DSM 4137 for the novel neuroprotectant polyketide meridamycin. Microbiology 2006, 152(Pt 12), 3507-15. (Pubitemid 46040670)
49. Liu, H.; Jiang, H.; Haltli, B.; Kulowski, K.; Muszynska, E.; Feng, X.; Summers, M.; Young, M.; Graziani, E.; Koehn, F.; Carter, G. T.; He, M., Rapid Cloning and Heterologous Expression of the Meridamycin Biosynthetic Gene Cluster Using a Versatile Escherichia coliâ' Streptomyces Artificial Chromosome Vector, pSBACâSyen;. Journal of Natural Products 2009, 72(3), 389-395.
50. Park, J. W.; Park, S. R.; Han, A. R.; Ban, Y.-H.; Yoo, Y J.; Kim, E. J.; Kim, E.; Yoon, Y J., Generation of reduced macrolide analogs by regio-specific biotransformation. J Antibiot 2010, 64(1), 155-157.
51. Qu, X.; Jiang, N.; Xu, F.; Shao, L.; Tang, G.; Wilkinson, B.; Liu, W., Cloning, sequencing and characterization of the biosynthetic gene cluster of sanglifehrin A, a potent cyclophilin inhibitor. Mol Biosyst 2011, 7(3), 852-61.
52. Hui, K. K. W.; Liadis, N.; Robertson, J.; Kanungo, A.; Henderson, J. T, Calcineurin inhibition enhances motor neuron survival following injury. Journal of Cellular and Molecular Medicine 2010, 14(3), 671-686.
53. Park, K. K.; Liu, K.; Hu, Y.; Smith, P. D.; Wang, C.; Cai, B.; Xu, B.; Connolly, L.; Kramvis, I.; Sahin, M.; He, Z., Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322(5903), 963-6.
54. Steiner, J. P.; Connolly, M. A.; Valentine, H. L.; Hamilton, G. S.; Dawson, T. M.; Hester, L.; Snyder, S. H., Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med 1997, 3(4), 421-8. (Pubitemid 27145684)
55. Gerard, M.; Deleersnijder, A.; Demeulemeester, J.; Debyser, Z.; Baekelandt, V, Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. Mol Neurobiol 2011, 44(1), 13-27.
56. Klettner, A.; Herdegen, T, The immunophilin-ligands FK506 and V-10, 367 mediate neuroprotection by the heat shock response. Br J Pharmacol 2003, 138(5), 1004-12. (Pubitemid 36390658)
57. Ruan, B.; Pong, K.; Jow, F.; Bowlby, M.; Crozier, R. A.; Liu, D.; Liang, S.; Chen, Y.; Mercado, M. L.; Feng, X.; Bennett, F.; von Schack, D.; McDonald, L.; Zaleska, M. M.; Wood, A.; Reinhart, P. H.; Magolda, R. L.; Skotnicki, J.; Pangalos, M. N; Koehn, F E.; Carter, G. T.; Abou-Gharbia, M.; Graziani, E. I, Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proceedings of the National Academy of Sciences 2008, 105(1), 33-38.
58. Liu, D.; McIlvain, H. B.; Fennell, M.; Dunlop, J.; Wood, A.; Zaleska, M. M.; Graziani, E. I; Pong, K., Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. J Neurosci Methods 2007, 163(2), 310-20. (Pubitemid 46874607)
59. Summers, M. Y; Leighton, M.; Liu, D.; Pong, K.; Graziani, E. I, 3-Normeridamycin: A Potent Non-Immunosuppressive Immunophilin Ligand is Neuroprotective in Dopaminergic Neurons. J Antibiot 2006, 59(3), 184-189. (Pubitemid 43667149)
60. Revill, W. P.; Voda, J.; Reeves, C. R.; Chung, L.; Schirmer, A.; Ashley, G.; Carney, J. R.; Fardis, M.; Carreras, C. W.; Zhou, Y.; Feng, L.; Tucker, E.; Robinson, D.; Gold, B. G., Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Ther 2002, 302(3), 1278-85. (Pubitemid 34920253)
61. Gold, B. G.; Armistead, D. M.; Wang, M. S., Non-FK506-binding protein-12 neuroimmunophilin ligands increase neurite elongation and accelerate nerve regeneration. J Neurosci Res 2005, 80(1), 56-65. (Pubitemid 40577293)
62. Birge, R. B.; Wadsworth, S.; Akakura, R.; Abeysinghe, H.; Kanojia, R.; MacIelag, M.; Desbarats, J.; Escalante, M.; Singh, K.; Sundarababu, S.; Parris, K.; Childs, G.; August, A.; Siekierka, J.; Weinstein, D. E., A role for schwann cells in the neuroregenerative effects of a non-immunosuppressive fk506 derivative, jnj460. Neuroscience 2004, 124(2), 351-66. (Pubitemid 38229655)
63. Zhao, L.; Liu, H.; Wang, L.; Li, S., Modeling and synthesis of non-cyclic derivatives of GPI-1046 as potential FKBP ligands with neurotrophic properties. Bioorganic & Medicinal Chemistry Letters 2006, 16(16), 4385-4390.
64. Costantini, L. C.; Isacson, O., Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. Exp Neurol 2000, 164(1), 60-70. (Pubitemid 30490723)
65. Costantini, L. C.; Chaturvedi, P.; Armistead, D. M.; McCaffrey, P. G.; Deacon, T. W.; Isacson, O., A Novel Immunophilin Ligand: Distinct Branching Effects on Dopaminergic Neurons in Culture and Neurotrophic Actions after Oral Administration in an Animal Model of Parkinson's Disease. Neurobiology of Disease 1998, 5(2), 97-106. (Pubitemid 28430720)
66. Wei, L.; Steiner, J. P.; Hamilton, G. S.; Wu, Y.-Q., Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives. Bioorganic & Medicinal Chemistry Letters 2004, 14(17), 4549-4551. (Pubitemid 39043983)
67. Price, R. D.; Yamaji, T.; Yamamoto, H.; Higashi, Y.; Hanaoka, K.; Yamazaki, S.; Ishiye, M.; Aramori, I.; Matsuoka, N.; Mutoh, S., FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. European Journal of Pharmacology 2005, 509(1), 11-19. (Pubitemid 40248780)
68. Yamazaki, S.; Yamaji, T.; Murai, N.; Yamamoto, H.; Price, R. D.; Matsuoka, N.; Mutoh, S., FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. Neuropharmacology 2008, 55(7), 1226-1230.
69. Kupina, N. C.; Detloff, M. R.; Dutta, S.; Hall, E. D., Neuroimmunophilin Ligand V-10, 367 Is Neuroprotective After 24-Hour Delayed Administration in a Mouse Model of Diffuse Traumatic Brain Injury. J Cereb Blood Flow Metab 2002, 22(10), 1212-1221.
70. Edlich, F.; Weiwad, M.; Wildemann, D.; Jarczowski, F.; Kilka, S.; Moutty, M.-C.; Jahreis, G.; Lucke, C.; Schmidt, W.; Striggow, F.; Fischer, G., The Specific FKBP38 Inhibitor N-(N', N'-Dimethylcarboxamidomethyl) cycloheximide Has Potent Neuroprotective and Neurotrophic Properties in Brain Ischemia. J. Biol. Chem. 2006, 281(21), 14961-14970. (Pubitemid 43855200)
71. Costantini, L. C.; Cole, D.; Chaturvedi, P.; Isacson, O., Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur J Neurosci 2001, 13(6), 1085-92. (Pubitemid 32275745)
72. Steiner, J. P.; Hamilton, G. S.; Ross, D. T.; Valentine, H. L.; Guo, H.; Connolly, M. A.; Liang, S.; Ramsey, C.; Li, J. H.; Huang, W.; Howorth, P.; Soni, R.; Fuller, M.; Sauer, H.; Nowotnik, A. C.; Suzdak, P. D., Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A 1997, 94(5), 2019-24. (Pubitemid 27113954)
73. Kubota, M.; Kasahara, T.; Iwamoto, K.; Komori, A.; Ishiwata, M.; Miyauchi, T.; Kato, T., Therapeutic implications of down-regulation of cyclophilin D in bipolar disorder. Int J Neuropsychopharmacol 2010, 13(10), 1355-68.
74. Minematsu, T.; Lee, J.; Zha, J.; Moy, S.; Kowalski, D.; Hori, K.; Ishibashi, K.; Usui, T.; Kamimura, H., Time-dependent inhibitory effects of (1R, 9S, 12S, 13R, 14S, 17R, 18E, 21S, 23S, 24R, 25S, 27R)-1, 14-dihydroxy-12-(E)-2- [(1R, 3R, 4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-17-(2-oxopropyl)-11, 28-dioxa-4-azatricyclo [22.3.1.0 (4.9)]octacos-18-ene-2, 3, 10, 16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. Drug Metab Dispos 38(2), 249-59.
75. Kawai, M.; Lane, B. C.; Hsieh, G. C.; Mollison, K. W.; Carter, G. W.; Luly, J. R., Structure-activity profiles of macrolactam immunosuppressant FK-506 analogues. FEBS Lett 1993, 316(2), 107-13. (Pubitemid 23025039)
76. Ocain, T. D.; Longhi, D.; Stefan, R. J.; Caccese, R. G.; Sehgal, S. N., Biochem. Biophys. Res. Commun. 1993, 192(null), 1340.
77. Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thomson, J. A.; DeCenzo, M. T.; Futer, O.; Livingston, D. J.; Murcko, M. A.; Yamashita, M. M.; Navia, M. A., Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr D Biol Crystallogr 1995, 51(Pt 4), 522-8.
78. Armistead, D., M, Methods and compositions for stimulating neurite growth. WO 96/41609 1996.
79. Germann, U. A. S. Dlna; Mason, Valerie S; Zelle, Robert E; Duffy, John P; Galullo, Vincent; Armistead, David M; Saunders, Jeffrey O; Boger, Joshua; Harding, Matthew W, Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-Caner Drugs 1997, 8, 125-140. (Pubitemid 27102228)
80. Dey, S., Biricodar. Vertex Pharmaceuticals. Curr Opin Investig Drugs 2002, 3(5), 818-23.
81. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.; Smith, D.; O'Donnell, R.; O'Connor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F., Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience 1999, 88(1), 257-67. (Pubitemid 28440407)
82. Bocquet, A.; Lorent, G.; Fuks, B.; Grimee, R.; Talaga, P.; Daliers, J.; Klitgaard, H., Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J Pharmacol 2001, 415(2-3), 173-80. (Pubitemid 32239461)
83. Zhao, L.; Huang, W.; Liu, H.; Wang, L.; Zhong, W.; Xiao, J.; Hu, Y.; Li, S., FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5, 5-dimethyl-2-(4- thiazolidine) carboxylates. J Med Chem 2006, 49(14), 4059-71. (Pubitemid 44036653)
84. Graziani, F.; Aldegheri, L.; Terstappen, G. C., High Throughput Scintillation Proximity Assay for the Identification of FKBP-12 Ligands. J Biomol Screen 1999, 4(1), 3-7. (Pubitemid 29227418)
85. Rabinowitz, M.; Seneci, P.; Rossi, T.; Dal Cin, M.; Deal, M.; Terstappen, G., Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands. Bioorg Med Chem Lett 2000, 10(10), 1007-10. (Pubitemid 30406453)
86. Sich, C.; Improta, S.; Cowley, D. J.; Guenet, C.; Merly, J. P.; Teufel, M.; Saudek, V., Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on protein dynamics. Eur J Biochem 2000, 267(17), 5342-55.
87. Gerard, M.; Deleersnijder, A. I.; DaniÃls, V.; Schreurs, S.; Munck, S.; Reumers, V.; Pottel, H.; Engelborghs, Y.; Van den Haute, C.; Taymans, J.-M.; Debyser, Z.; Baekelandt, V., Inhibition of FK506 Binding Proteins Reduces α-Synuclein Aggregation and Parkinson's Disease-Like Pathology. The Journal of Neuroscience 2010, 30(7), 2454-2463.
88. Marshall, V. L.; Grosset, D. G., GPI-1485 (Guilford). Curr Opin Investig Drugs 2004, 5(1), 107-12.
89. Gold, B. G.; Densmore, V.; Shou, W.; and, M. M. M.; Gordon1, H. S., Immunophilin FK506-Binding Protein 52 (Not FK506-Binding Protein 12) Mediates the Neurotrophic Action of FK506. J. Pharmacol. Exper. Therap. 1999, 289(3), 1202-1210 (Pubitemid 29246645)
90. Cole, D. G. O. Stephan. Pharmacological activities of neurophilin ligands. immunophilins in the Brain. FKBP Ligands: Novel Strategies for the Treatment of Neurodegenerative Disorders. proceedings from the conference on neuroimmunophilins, 1st, schlangenbad, germany. 1999, 109-116.
91. Polydefkis, M.; Sirdofsky, M.; Hauer, P.; Petty, B. G.; Murinson, B.; McArthur, J. C., Factors influencing nerve regeneration in a trial of timcodar dimesylate. Neurology 2006, 66(2), 259-61. (Pubitemid 43970169)
92. Hahn, K.; Sirdofsky, M.; Brown, A.; Ebenezer, G.; Hauer, P.; Miller, C.; Polydefkis, M., Collateral sprouting of human epidermal nerve fibers following intracutaneous axotomy. J Peripher Nerv Syst 2006, 11(2), 142-7. (Pubitemid 43894081)
93. Norville, I. H.; O'Shea, K.; Sarkar-Tyson, M.; Zheng, S.; Titball, R. W.; Varani, G.; Harmer, N. J., The structure of a Burkholderia pseudomallei immunophilin-inhibitor complex reveals new approaches to antimicrobial development. Biochem J 437(3), 413-22.
94. Shim, S.; Yuan, J. P.; Kim, J. Y.; Zeng, W.; Huang, G.; Milshteyn, A.; Kern, D.; Muallem, S.; Ming, G.-l.; Worley, P. F., Peptidyl-Prolyl Isomerase FKBP52 Controls Chemotropic Guidance of Neuronal Growth Cones via Regulation of TRPC1 Channel Opening. Neuron 2009, 64(4), 471-483.
95. Quintá, H. R.; Maschi, D.; Gomez-Sanchez, C.; Piwien-Pilipuk, G.; Galigniana, M. D., Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. Journal of Neurochemistry 2010, 115(3), 716-734.
96. Chambraud, B.; Sardin, E.; Giustiniani, J.; Dounane, O.; Schumacher, M.; Goedert, M.; Baulieu, E. E., A role for FKBP52 in Tau protein function. Proc Natl Acad Sci U S A 2010, 107(6), 2658-63.
97. Jinwal, U. K.; Koren, J., 3rd; Borysov, S. I.; Schmid, A. B.; Abisambra, J. F.; Blair, L. J.; Johnson, A. G.; Jones, J. R.; Shults, C. L.; O'Leary, J. C., 3rd; Jin, Y.; Buchner, J.; Cox, M. B.; Dickey, C. A., The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci 2010, 30(2), 591-9.
98. Chambraud, B.; Belabes, H.; Fontaine-Lenoir, V.; Fellous, A.; Baulieu, E. E., The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEBJ. 2007, 21(11), 2787-97. (Pubitemid 47372746)
99. Huse, M.; Chen, Y. G.; Massague, J.; Kuriyan, J., Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999, 96(3), 425-36. (Pubitemid 29077596)
100. Ahearn, I. M.; Tsai, F. D.; Court, H.; Zhou, M.; Jennings, B. C.; Ahmed, M.; Fehrenbacher, N.; Linder, M. E.; Philips, M. R., FKBP12 Binds to Acylated H-Ras and Promotes Depalmitoylation. Molecular Cell 2011, 41(2), 173-185.
101. Gerard, M.; Debyser, Z.; Desender, L.; Kahle, P. J.; Baert, J.; Baekelandt, V.; Engelborghs, Y., The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. Faseb J 2006, 20(3), 524-6. (Pubitemid 46671237)
102. Deleersnijder, A.; Van Rompuy, A. S.; Desender, L.; Pottel, H.; Buee, L.; Debyser, Z.; Baekelandt, V.; Gerard, M., Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of {alpha}-synuclein aggregation. J Biol Chem 2011.
103. 2+ uptake into the endoplasmic reticulum and mitochondria. J Biol Chem 2001, 276(26), 23329-40.
104. 2+ accumulation mechanisms. J Physiol 2000, 525 Pt 3, 681-93. (Pubitemid 30426789)
105. 2+-ATPase by macrocyclic lactones and cyclosporin A. Biochem J 2002, 366(Pt 1), 255-63. (Pubitemid 34971825)
106. Rosado, J. A.; Pariente, J. A.; Salido, G. M.; Redondo, P. C., SERCA2b Activity Is Regulated by Cyclophilins in Human Platelets. Arterioscler Thromb Vasc Biol 2010, 30(3), 419-425.
107. Caporello, E.; Nath, A.; Slevin, J.; Galey, D.; Hamilton, G.; Williams, L.; Steiner, J. P.; Haughey, N. J., The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem 2006, 98(1), 146-55. (Pubitemid 43882940)
108. Goel, M.; Garcia, R.; Estacion, M.; Schilling, W. P., Regulation of Drosophila TRPL channels by immunophilin FKBP59. J Biol Chem 2001, 276(42), 38762-73.
109. Sinkins, W. G.; Goel, M.; Estacion, M.; Schilling, W. P., Association of immunophilins with mammalian TRPC channels. J Biol Chem 2004, 279(33), 34521-9. (Pubitemid 39318080)
110. 2+ channel TRPV5. Am J Physiol Renal Physiol 2006, 290(5), F1253-1259. (Pubitemid 43724926)
111. Arceci, R. J.; Stieglitz, K.; Bierer, B. E., Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992, 80(6), 1528-36.
112. Guo, C.; Reich, S.; Showalter, R.; Villafranca, E.; Dong, L., A concise synthesis of AG5473/5507 utilizing N-acyliminium ion chemistry. Tetrahedron Letters 2000, 41(28), 5307-5311. (Pubitemid 30450783)
113. Hudack RA Jr, B. N, Guo C., Deal J, Dong L, Fay LK, Caprathe B, Chatterjee A, Vanderpool D, Bigge C., Showalter R, Bender S, Augelli-Szafran CE, Lunney E, Hou X., Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands. J. Med. Chem 2006, 1202-1206. (Pubitemid 43221667)
114. Guo, C.; Dong, L.; Kephart, S.; Hou, X., An efficient synthesis of sulfamides. Tetrahedron Letters 2010, 51(21), 2909-2913.
115. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W., Discovering highaffinity ligands for proteins: SAR by NMR. Science 1996, 274(5292), 1531-4. (Pubitemid 26403929)
116. Röhrig, Christoph H.; Overhand, C. L. J.-Y. G. G. S. M., Fragment-Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity. ChemMedChem 2007, 2(7), 1054-1070.
117. Stebbins, J. L.; Zhang, Z.; Chen, J.; Wu, B.; Emdadi, A.; Williams, M. E.; Cashman, J.; Pellecchia, M., Nuclear Magnetic Resonance Fragment-Based Identification of Novel FKBP12 Inhibitors. J. Med. Chem. 2007.
118. Blackburn, E. A.; Maclean, J. K.; Sherborne, B. S.; Walkinshaw, M. D., Estimating the affinity of protein-ligand complex from changes to the charge-state distribution of a protein in electrospray ionization mass spectrometry. Biochem Biophys Res Commun 2010, 403(2), 190-3.
119. Cioffi, D. L.; Hubler, T. R.; Scammell, J. G., Organization and function of the FKBP52 and FKBP51 genes. Current Opinion in Pharmacology 2011, In Press, Corrected Proof.
120. Sivils, J. C.; Storer, C. L.; Galigniana, M. D.; Cox, M. B., Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52). Curr Opin Pharmacol 2011.
121. Yong, W.; Bao, S.; Chen, H.; Li, D.; Sanchez, E. R.; Shou, W., Mice Lacking Protein Phosphatase 5 Are Defective in Ataxia Telangiectasia Mutated (ATM)-mediated Cell Cycle Arrest. J. Biol. Chem. 2007, 282(20), 14690-14694. (Pubitemid 47093323)
122. Attwood, B. K.; Bourgognon, J. M.; Patel, S.; Mucha, M.; Schiavon, E.; Skrzypiec, A. E.; Young, K. W.; Shiosaka, S.; Korostynski, M.; Piechota, M.; Przewlocki, R.; Pawlak, R., Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 2011, 473(7347), 372-5.
123. Jaaskelainen, T.; Makkonen, H.; Palvimo, J. J., Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 2011.
124. Scharf, S. H.; Liebl, C.; Binder, E. B.; Schmidt, M. V.; Muller, M. B., Expression and regulation of the Fkbp5 gene in the adult mouse brain. PLoS One 6(2), e16883.
125. Binder, E. B., The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009, 34(Supplement 1), S186-S195.
126. Zou, Y.-F.; Wang, F.; Feng, X.-L.; Li, W.-F.; Tao, J.-H.; Pan, F.-M.; Huang, F.; Su, H., Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neuroscience Letters 2010, 484(1), 56-61.
127. Hartmann, J.; Wagner, K. V.; Liebl, C.; Scharf, S. H.; Wang, X.-D.; Wolf, M.; Hausch, F.; Rein, T.; Schmidt, U.; Touma, C.; Cheung-Flynn, J.; Cox, M. B.; Smith, D. F.; Holsboer, F.; Müller, M. B.; Schmidt, M. V., The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 2011, In Press, Corrected Proof.
128. Touma, C.; Gassen, N. C.; Herrmann, L.; Cheung-Flynn, J.; Büll, D. R.; Ionescu, I. A.; Heinzmann, J. M.; Knapman, A.; Siebertz, A.; Depping, A. M.; Hartmann, J.; Hausch, F.; Schmidt, M. V.; Holsboer, F.; Ising, M.; Cox, M. B.; Schmidt, U.; Rein, T., FKBP5 shapes stress responsiveness: Modulation of neuroendocrine reactivity and coping behavior. Biological Psychiatry 2011, in Press, Corrected Proof.
129. Romano S. M. M., Romano MF, FKBP51 and the NF-kB regulatory pathway in cancer. Current Opinion in Pharmacology 2011, 1-6.
130. Li, L.; Lou, Z.; Wang, L., The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2010, 104(1), 19-23.
131. Periyasamy, S.; Hinds, T., Jr.; Shemshedini, L.; Shou, W.; Sanchez, E. R., FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010, 29(11), 1691-1701.
132. Ni, L.; Yang, C. S.; Gioeli, D.; Frierson, H.; Toft, D. O.; Paschal, B. M., FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells. Mol Cell Biol 2010, 30(5), 1243-53.
133. Romano, S.; DAngelillo, A.; Pacelli, R.; Staibano, S.; De Luna, E.; Bisogni, R.; Eskelinen, E. L.; Mascolo, M.; Cali, G.; Arra, C.; Romano, M. F., Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. Cell Death Differ 2010, 17(1), 145-57.
134. Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P. O.; Bergamini, G.; Croughton, K.; Cruciat, C.; Eberhard, D.; Gagneur, J.; Ghidelli, S.; Hopf, C.; Huhse, B.; Mangano, R.; Michon, A. M.; Schirle, M.; Schlegl, J.; Schwab, M.; Stein, M. A.; Bauer, A.; Casari, G.; Drewes, G.; Gavin, A. C.; Jackson, D. B.; Joberty, G.; Neubauer, G.; Rick, J.; Kuster, B.; Superti-Furga, G., A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004, 6(2), 97-105. (Pubitemid 38425708)
135. Pei, H.; Li, L.; Fridley, B. L.; Jenkins, G. D.; Kalari, K. R.; Lingle, W.; Petersen, G.; Lou, Z.; Wang, L., FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt. Cancer Cell 2009, 16(3), 259-266.
136. Riggs, D. L.; Roberts, P. J.; Chirillo, S. C.; Cheung-Flynn, J.; Prapapanich, V.; Ratajczak, T.; Gaber, R.; Picard, D.; Smith, D. F., The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. Embo J 2003, 22(5), 1158-67. (Pubitemid 36313599)
137. Davies, T. H.; Ning, Y. M.; Sanchez, E. R., Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005, 44(6), 2030-8. (Pubitemid 40223631)
138. Westberry, J. M.; Sadosky, P. W.; Hubler, T. R.; Gross, K. L.; Scammell, J. G., Glucocorticoid resistance in squirrel monkeys results from a combination of a transcriptionally incompetent glucocorticoid receptor and overexpression of the glucocorticoid receptor co-chaperone FKBP51. J Steroid Biochem Mol Biol 2006, 100(1-3), 34-41. (Pubitemid 44088616)
139. Kralli, A.; Yamamoto, K. R., An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J Biol Chem 1996, 271(29), 17152-6. (Pubitemid 26244266)
140. Marsaud, V.; Mercier-Bodard, C.; Fortin, D.; Le Bihan, S.; Renoir, J. M., Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J Steroid Biochem Mol Biol 1998, 66(1-2), 11-25. (Pubitemid 28335451)
141. Bracher, A.; Kozany, C.; Thost, A. K.; Hausch, F., Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90. Acta Crystallogr D Biol Crystallogr 67(Pt 6), 549-59.
142. Kozany, C.; März, A.; Kress, C.; Hausch, F., Fluorescent Probes to Characterise FK506-Binding Proteins. ChemBioChem 2009, 10(8), 1402-1410.
143. Bell, A.; Monaghan, P.; Page, A. P., Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action. Int J Parasitol 2006, 36(3), 261-76. (Pubitemid 43376108)
144. Kohler, R.; Fanghanel, J.; Konig, B.; Luneberg, E.; Frosch, M.; Rahfeld, J. U.; Hilgenfeld, R.; Fischer, G.; Hacker, J.; Steinert, M., Biochemical and functional analyses of the Mip protein: influence of the N-terminal half and of peptidylprolyl isomerase activity on the virulence of Legionella pneumophila. Infect Immun 2003, 71(8), 4389-97. (Pubitemid 36919904)
145. Moro, A.; Ruiz-Cabello, F.; Fernandez-Cano, A.; Stock, R. P.; Gonzalez, A., Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. EMBO J 1995, 14(11), 2483-90.
146. Oz, H. S.; Hughes, W. T.; Thomas, E. K.; McClain, C. J., Effects of immunomodulators on acute Trypanosoma Cruzi infection in mice. Med Sci Monit 2002, 8(6), BR208-11. (Pubitemid 34694641)
147. Ceymann, A.; Horstmann, M.; Ehses, P.; Schweimer, K.; Paschke, A. K.; Steinert, M.; Faber, C., Solution structure of the Legionella pneumophila Mip-rapamycin complex. BMC Struct Biol 2008, 8, 17.
148. Juli, C.; Sippel, M.; Jager, J.; Thiele, A.; Weiwad, M.; Schweimer, K.; Rosch, P.; Steinert, M.; Sotriffer, C. A.; Holzgrabe, U., Pipecolic Acid Derivatives As Small-Molecule Inhibitors of the Legionella MIP Protein. J Med Chem 2010.
149. Norville, I. H.; O'Shea, K.; Sarkar-Tyson, M.; Zheng, S.; Titball, R. W.; Varani, G.; Harmer, N. J., The structure of a Burkholderia pseudomallei immunophilin-inhibitor complex reveals new approaches to antimicrobial development. Biochem J 2011, 437(3), 413-22.
150. Monaghan, P.; Fardis, M.; Revill, W. P.; Bell, A., Antimalarial effects of macrolactones related to FK520 (ascomycin) are independent of the immunosuppressive properties of the compounds. J Infect Dis 2005, 191(8), 1342-9.
151. Rotonda, J.; Burbaum, J. J.; Chan, H. K.; Marcy, A. I.; Becker, J. W., Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. J Biol Chem 1993, 268(11), 7607-9. (Pubitemid 23120320)
152. Kumar, R.; Adams, B.; Musiyenko, A.; Shulyayeva, O.; Barik, S., The FK506-binding protein of the malaria parasite, Plasmodium falciparum, is a FK506-sensitive chaperone with FK506-independent calcineurin-inhibitory activity. Mol Biochem Parasitol 2005, 141(2), 163-73. (Pubitemid 40591560)
153. Hopkins, S.; Scorneaux, B.; Huang, Z.; Murray, M. G.; Wring, S.; Smitley, C.; Harris, R.; Erdmann, F.; Fischer, G.; Ribeill, Y., SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010, 54(2), 660-72.
154. Baumgrass, R.; Zhang, Y.; Erdmann, F.; Thiel, A.; Weiwad, M.; Radbruch, A.; Fischer, G., Substitution in position 3 of cyclosporin A abolishes the cyclophilin-mediated gain-of-function mechanism but not immunosuppression. J Biol Chem 2004, 279(4), 2470-9. (Pubitemid 38114230)
155. Puyang, X.; Poulin, D. L.; Mathy, J. E.; Anderson, L. J.; Ma, S.; Fang, Z.; Zhu, S.; Lin, K.; Fujimoto, R.; Compton, T.; Wiedmann, B., Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors. Antimicrob. Agents Chemother. 2010, 54(5), 1981-1987.
156. Goto, K.; Watashi, K.; Inoue, D.; Hijikata, M.; Shimotohno, K., Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Science 2009, 100(10), 1943-1950.
157. Gregory, M. A.; Bobardt, M.; Obeid, S.; Chatterji, U.; Coates, N. J.; Foster, T.; Gallay, P.; Leyssen, P.; Moss, S. J.; Neyts, J.; Nur-e-Alam, M.; Paeshuyse, J.; Piraee, M.; Suthar, D.; Warneck, T.; Zhang, M.-Q.; Wilkinson, B., Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family. Antimicrob. Agents Chemother. 2011, 55(5), 1975-1981.
158. Morohashi, K.; Sahara, H.; Watashi, K.; Iwabata, K.; Sunoki, T.; Kuramochi, K.; Takakusagi, K.; Miyashita, H.; Sato, N.; Tanabe, A.; Shimotohno, K.; Kobayashi, S.; Sakaguchi, K.; Sugawara, F., Cyclosporin A Associated Helicase-Like Protein Facilitates the Association of Hepatitis C Virus RNA Polymerase with Its Cellular Cyclophilin B. PLoS ONE 2011, 6(4), e18285.
159. Coelmont, L.; Hanoulle, X.; Chatterji, U.; Berger, C.; Snoeck, J.; Bobardt, M.; Lim, P.; Vliegen, I.; Paeshuyse, J.; Vuagniaux, G. g.; Vandamme, A.-M.; Bartenschlager, R.; Gallay, P.; Lippens, G.; Neyts, J., DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A. PLoS ONE 2010, 5(10), e13687.
160. Crabbe, R.; Vuagniaux, G.; Dumont, J. M.; Nicolas-Metral, V.; Marfurt, J.; Novaroli, L., An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs 2009, 18(2), 211-20.
161. Flisiak, R.; Dumont, J. M.; Crabbe, R., Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007, 16(9), 1345-54. (Pubitemid 47491405)
162. Simon, N.; Dailly, E.; Combes, O.; Malaurie, E.; Lemaire, M.; Tillement, J. P.; Urien, S., Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 1998, 45(2), 173-5. (Pubitemid 28045688)
163. Suzuki, J.; Jin, Z.-G.; Meoli, D. F.; Matoba, T.; Berk, B. C., Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells. Circulation Research 2006, 98(6), 811-817.
164. Arora, K.; Gwinn, W. M.; Bower, M. A.; Watson, A.; Okwumabua, I.; MacDonald, H. R.; Bukrinsky, M. I.; Constant, S. L., Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005, 175(1), 517-22. (Pubitemid 40884357)
165. Malesevic, M.; Kuhling, J.; Erdmann, F.; Balsley, M. A.; Bukrinsky, M. I.; Constant, S. L.; Fischer, G., A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem Int Ed Engl 2010, 49(1), 213-5.
166. Zhang, Y.; Erdmann, F.; Baumgrass, R.; Schutkowski, M.; Fischer, G., Unexpected side chain effects at residue 8 of cyclosporin a derivatives allow photoswitching of immunosuppression. J Biol Chem 2005, 280(6), 4842-50. (Pubitemid 40288657)
167. Balsley, M. A.; Malesevic, M.; Stemmy, E. J.; Gigley, J.; Jurjus, R. A.; Herzog, D.; Bukrinsky, M. I.; Fischer, G.; Constant, S. L., A cellimpermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation. J Immunol 2010, 185(12), 7663-70.
168. Giorgio, V.; Soriano, M. E.; Basso, E.; Bisetto, E.; Lippe, G.; Forte, M. A.; Bernardi, P., Cyclophilin D in mitochondrial pathophysiology. Biochim Biophys Acta 2010, 1797(6-7), 1113-8.
169. Fujimoto, K.; Chen, Y.; Polonsky, K. S.; Dorn, G. W., 2nd, Targeting cyclophilin D and the mitochondrial permeability transition enhances betacell survival and prevents diabetes in Pdx1 deficiency. Proc Natl Acad Sci U S A 2010, 107(22), 10214-9.
170. Piot, C.; Croisille, P.; Staat, P.; Thibault, H.; Rioufol, G.; Mewton, N.; Elbelghiti, R.; Cung, T. T.; Bonnefoy, E.; Angoulvant, D.; Macia, C.; Raczka, F.; Sportouch, C.; Gahide, G.; Finet, G.; Andre-Fouet, X.; Revel, D.; Kirkorian, G.; Monassier, J. P.; Derumeaux, G.; Ovize, M., Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008, 359(5), 473-81.
171. Merlini, L.; Angelin, A.; Tiepolo, T.; Braghetta, P.; Sabatelli, P.; Zamparelli, A.; Ferlini, A.; Maraldi, N. M.; Bonaldo, P.; Bernardi, P., Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci U S A 2008, 105(13), 5225-9. (Pubitemid 351738538)
172. Seizer, P.; Ochmann, C.; Schonberger, T.; Zach, S.; Rose, M.; Borst, O.; Klingel, K.; Kandolf, R.; MacDonald, H. R.; Nowak, R. A.; Engelhardt, S.; Lang, F.; Gawaz, M.; May, A. E., Disrupting the EMMPRIN (CD147) - Cyclophilin A Interaction Reduces Infarct Size and Preserves Systolic Function After Myocardial Ischemia and Reperfusion. Arterioscler Thromb Vasc Biol 2011, 31(6), 1377-1386.
173. Kajitani, K.; Fujihashi, M.; Kobayashi, Y.; Shimizu, S.; Tsujimoto, Y.; Miki, K., Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96-A resolution. Proteins 2008, 70(4), 1635-9. (Pubitemid 351304121)
174. Malouitre, S.; Dube, H.; Selwood, D.; Crompton, M., Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochemical Journal 2010, 425(1), 137-148.
175. Guichou, J. F.; Viaud, J.; Mettling, C.; Subra, G.; Lin, Y. L.; Chavanieu, A., Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem 2006, 49(3), 900-10. (Pubitemid 43221638)
176. Gaali, S.; Kozany, C.; Hoogeland, B.; Klein, M.; Hausch, F., Facile Synthesis of a Fluorescent Cyclosporin A Analogue To Study Cyclophilin 40 and Cyclophilin 18 Ligands. ACS Medicinal Chemistry Letters 2010, 1(9), 536-539.
177. 2+ uptake/release. Acta Pharmacol Sin 2005, 26(10), 1201-11. (Pubitemid 41406636)
178. Li, J.; Chen, J.; Zhang, L.; Wang, F.; Gui, C.; Qin, Y.; Xu, Q.; Liu, H.; Nan, F.; Shen, J.; Bai, D.; Chen, K.; Shen, X.; Jiang, H., One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation. Bioorg Med Chem 2006, 14(16), 5527-34.
179. Li, J.; Chen, J.; Gui, C.; Zhang, L.; Qin, Y.; Xu, Q.; Zhang, J.; Liu, H.; Shen, X.; Jiang, H., Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay. Bioorg Med Chem 2006, 14(7), 2209-24. (Pubitemid 43254734)
180. Li, J.; Zhang, J.; Chen, J.; Luo, X.; Zhu, W.; Shen, J.; Liu, H.; Shen, X.; Jiang, H., Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay. J Comb Chem 2006, 8(3), 326-37. (Pubitemid 43798296)
181. Ni, S.; Yuan, Y.; Huang, J.; Mao, X.; Lv, M.; Zhu, J.; Shen, X.; Pei, J.; Lai, L.; Jiang, H.; Li, J., Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J Med Chem 2009, 52(17), 5295-8.
182. Li, J.; Tan, Z.; Tang, S.; Hewlett, I.; Pang, R.; He, M.; He, S.; Tian, B.; Chen, K.; Yang, M., Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg Med Chem 2009, 17(8), 3177-88.
183. Tan, Z.; Li, J.; Pang, R.; He, S.; He, M.; Tang, S.; Hewlett, I.; Yang, M., Screening and evaluation of thiourea derivatives for their HIV capsid and human cyclophilin A inhibitory activity. Med Chem Res 2011, 20, 314-320.
184. Mori, T.; Hidaka, M.; Lin, Y. C.; Yoshizawa, I.; Okabe, T.; Egashira, S.; Kojima, H.; Nagano, T.; Koketsu, M.; Takamiya, M.; Uchida, T., A dual inhibitor against prolyl isomerase Pin1 and cyclophilin discovered by a novel real-time fluorescence detection method. Biochem Biophys Res Commun 2011, 406(3), 439-43.
185. Yang, Y.; Moir, E.; Kontopidis, G.; Taylor, P.; Wear, M. A.; Malone, K.; Dunsmore, C. J.; Page, A. P.; Turner, N. J.; Walkinshaw, M. D., Structurebased discovery of a family of synthetic cyclophilin inhibitors showing a cyclosporin-A phenotype in Caenorhabditis elegans. Biochem Biophys Res Commun 2007, 363(4), 1013-9. (Pubitemid 47559156)
186. Dunsmore, C. J.; Malone, K. J.; Bailey, K. R.; Wear, M. A.; Florance, H.; Shirran, S.; Barran, P. E.; Page, A. P.; Walkinshaw, M. D.; Turner, N. J., Design and synthesis of conformationally constrained cyclophilin inhibitors showing a cyclosporin-A phenotype in C. elegans. Chembiochem 2011, 12(5), 802-10.
187. Dearmond, P. D.; West, G. M.; Anbalagan, V.; Campa, M. J.; Patz, E. F., Jr.; Fitzgerald, M. C., Discovery of novel cyclophilin A ligands using an H/D exchange-and mass spectrometry-based strategy. J Biomol Screen 2011, 15(9), 1051-62.
188. Clavaud, C.; Heckenroth, M.; Stricane, C.; Lelait, M. A.; Menez, A.; Dugave, C., Combinatorial self-assembly of cyclophilin hCyp-18 ligands through rhenium coordination. Chembiochem 2006, 7(9), 1352-5. (Pubitemid 44369086)
189. Clavaud, C.; Le Gal, J.; Thai, R.; Moutiez, M.; Dugave, C., Dynamic combinatorial self-assembly of cyclophilin hCyp-18 ligands through oxorhenium coordination. Chembiochem 2008, 9(11), 1823-9.
190. Daum, S.; Schumann, M.; Mathea, S.; Aumuller, T.; Balsley, M. A.; Constant, S. L.; de Lacroix, B. F.; Kruska, F.; Braun, M.; Schiene-Fischer, C., Isoform-specific inhibition of cyclophilins. Biochemistry 2009, 48(26), 6268-77.
191. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Colon-Bonilla, E.; Rich, D. H., Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 1991, 30(25), 6127-34.
192. Mori, T.; Itami, S.; Yanagi, T.; Tatara, Y.; Takamiya, M.; Uchida, T., Use of a Real-Time Fluorescence Monitoring System for High-Throughput Screening for Prolyl Isomerase Inhibitors. J Biomol Screen 2009, 14(4), 419-424.
193. Liu, J.; Chen, C. M.; Walsh, C. T., Human and Escherichia coli cyclophilins: sensitivity to inhibition by the immunosuppressant cyclosporin A correlates with a specific tryptophan residue. Biochemistry 1991, 30(9), 2306-10.
194. Park, S. T.; Aldape, R. A.; Futer, O.; Decenzo, M. T.; Livingston, D. J., PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. Journal of Biological Chemistry 1992, 267, 3316-3324.
195. Carreras, C. W.; Fu, H.; Santi, D. V., An FKBP12 binding assay based upon biotinylated FKBP12. Anal Biochem 2001, 298(1), 57-61. (Pubitemid 33030121)
196. Banaszynski, L. A.; Liu, C. W.; Wandless, T. J., Characterization of the FKBP-rapamycin-FRB ternary complex. J Am Chem Soc 2005, 127(13), 4715-21. (Pubitemid 40489629)
197. Mahendrarajah, K.; Dalby, P. A.; Wilkinson, B.; Jackson, S. E.; Main, E. R., A high-throughput fluorescence chemical denaturation assay as a general screen for protein-ligand binding. Anal Biochem 2011, 411(1), 155-7.
198. West, G. M.; Thompson, J. W.; Soderblom, E. J.; Dubois, L. G.; Dearmond, P. D.; Moseley, M. A.; Fitzgerald, M. C., Mass spectrometry-based thermal shift assay for protein-ligand binding analysis. Anal Chem 2010, 82(13), 5573-81.
199. Luker, K. E.; Smith, M. C.; Luker, G. D.; Gammon, S. T.; Piwnica-Worms, H.; Piwnica-Worms, D., Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 2004, 101(33), 12288-93. (Pubitemid 39145436)
200. Corson, T. W.; Aberle, N.; Crews, C. M., Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. ACS Chem. Biol. 2008.
201. Fegan, A.; White, B.; Carlson, J. C.; Wagner, C. R., Chemically controlled protein assembly: techniques and applications. Chem Rev 2010, 110(6), 3315-36.
202. Biggar, S. R.; Crabtree, G. R., Cell signaling can direct either binary or graded transcriptional responses. Embo J 2001, 20(12), 3167-76. (Pubitemid 32612004)
203. Biggar, S. R.; Crabtree, G. R., Chemically regulated transcription factors reveal the persistence of repressor-resistant transcription after disrupting activator function. J Biol Chem 2000, 275(33), 25381-90.
204. Rivera, V. M.; Clackson, T.; Natesan, S.; Pollock, R.; Amara, J. F.; Keenan, T.; Magari, S. R.; Phillips, T.; Courage, N. L.; Cerasoli, F., Jr.; Holt, D. A.; Gilman, M., A humanized system for pharmacologic control of gene expression. Nat Med 1996, 2(9), 1028-32. (Pubitemid 26306843)
205. Ye, X.; Rivera, V. M.; Zoltick, P.; Cerasoli, F., Jr.; Schnell, M. A.; Gao, G.; Hughes, J. V.; Gilman, M.; Wilson, J. M., Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999, 283(5398), 88-91. (Pubitemid 29045765)
206. Kohler, J. J.; Bertozzi, C. R., Regulating cell surface glycosylation by small molecule control of enzyme localization. Chem Biol 2003, 10(12), 1303-11. (Pubitemid 38042732)
207. Robinson, M. S.; Sahlender, D. A.; Foster, S. D., Rapid inactivation of proteins by rapamycin-induced rerouting to mitochondria. Dev Cell 2010, 18(2), 324-31.
208. Komatsu, T.; Kukelyansky, I.; McCaffery, J. M.; Ueno, T.; Varela, L. C.; Inoue, T., Organelle-specific, rapid induction of molecular activities and membrane tethering. Nat Meth 2010, 7(3), 206-208.
209. Liberles, S. D.; Diver, S. T.; Austin, D. J.; Schreiber, S. L., Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. Proc Natl Acad Sci U S A 1997, 94(15), 7825-30. (Pubitemid 27343733)
210. Stankunas, K.; Bayle, J. H.; Gestwicki, J. E.; Lin, Y. M.; Wandless, T. J.; Crabtree, G. R., Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol Cell 2003, 12(6), 1615-24. (Pubitemid 38037028)
211. Luengo, J. I.; Yamashita, D. S.; Dunnington, D.; Beck, A. K.; Rozamus, L. W.; Yen, H. K.; Bossard, M. J.; Levy, M. A.; Hand, A.; Newman-Tarr, T.; et al., Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. Chem Biol 1995, 2(7), 471-81.
212. Pollock, R.; Giel, M.; Linher, K.; Clackson, T., Regulation of endogenous gene expression with a small-molecule dimerizer. Nat Biotechnol 2002, 20(7), 729-33. (Pubitemid 34734141)
213. Inoue, T.; Heo, W. D.; Grimley, J. S.; Wandless, T. J.; Meyer, T., An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways. Nat Methods 2005, 2(6), 415-8. (Pubitemid 40916559)
214. Chong, H.; Ruchatz, A.; Clackson, T.; Rivera, V. M.; Vile, R. G., A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 2002, 5(2), 195-203. (Pubitemid 34144836)
215. Karpova, A. Y.; Tervo, D. G.; Gray, N. W.; Svoboda, K., Rapid and reversible chemical inactivation of synaptic transmission in genetically targeted neurons. Neuron 2005, 48(5), 727-35. (Pubitemid 41759424)
216. Indraccolo, S.; Moserle, L.; Tisato, V.; Gola, E.; Minuzzo, S.; Roni, V.; Persano, L.; Chieco-Bianchi, L.; Amadori, A., Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Ther 2006, 13(12), 953-65. (Pubitemid 43827337)
217. Vogel, R.; Mammeri, H.; Mallet, J., Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. Hum Gene Ther 2008, 19(2), 167-78. (Pubitemid 351271511)
218. Clemons, P. A.; Gladstone, B. G.; Seth, A.; Chao, E. D.; Foley, M. A.; Schreiber, S. L., Synthesis of Calcineurin-Resistant Derivatives of FK506 and Selection of Compensatory Receptors. Chemistry & Biology 2002, 9(1), 49-61. (Pubitemid 34155864)
219. Spencer, D. M.; Wandless, T. J.; Schreiber, S. L.; Crabtree, G. R., Controlling signal transduction with synthetic ligands. Science 1993, 262(5136), 1019-24. (Pubitemid 24035037)
220. Luo, Z.; Tzivion, G.; Belshaw, P. J.; Vavvas, D.; Marshall, M.; Avruch, J., Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996, 383(6596), 181-5. (Pubitemid 26303983)
221. Belshaw, P. J.; Spencer, D. M.; Crabtree, G. R.; Schreiber, S. L., Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol 1996, 3(9), 731-8. (Pubitemid 26368314)
222. Amara, J. F.; Clackson, T.; Rivera, V. M.; Guo, T.; Keenan, T.; Natesan, S.; Pollock, R.; Yang, W.; Courage, N. L.; Holt, D. A.; Gilman, M., A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A 1997, 94(20), 10618-23. (Pubitemid 27430783)
223. Keenan T. Y. D., Courage NL, Rollins CT, Pavone ME, Rivera VM, Yang W, Guo T, Amara JF, Clackson T, Gilman M, Holt DA., Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. Bioorganic & Medicinal Chemistry Letters 1998, 6(8), 1309-1335. (Pubitemid 28398966)
224. Clackson, T.; Yang, W.; Rozamus, L. W.; Hatada, M.; Amara, J. F.; Rollins, C. T.; Stevenson, L. F.; Magari, S. R.; Wood, S. A.; Courage, N. L.; Lu, X.; Cerasoli, F., Jr.; Gilman, M.; Holt, D. A., Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A 1998, 95(18), 10437-42. (Pubitemid 28413085)
225. Nourse, M. B.; Rolle, M. W.; Pabon, L. M.; Murry, C. E., Selective control of endothelial cell proliferation with a synthetic dimerizer of FGF receptor-1. Lab Invest 2007, 87(8), 828-35. (Pubitemid 47077262)
226. Belshaw, P. J.; Schoepfer, J. G.; Liu, K.-Q.; Morrison, K. L.; Schreiber, S. L., Rational Design of Orthogonal Receptor-Ligand Combinations. Angewandte Chemie International Edition in English 1995, 34(19), 2129-2132.
227. Belshaw, P. J.; Schreiber, S. L., Cell-Specific Calcineurin Inhibition by a Modified Cyclosporin. Journal of the American Chemical Society 1997, 119(7), 1805-1806. (Pubitemid 27145535)
228. Yang, X.; Chang, H. Y.; Baltimore, D., Autoproteolytic activation of procaspases by oligomerization. Mol Cell 1998, 1(2), 319-25.
229. Li, Z. Y.; Otto, K.; Richard, R. E.; Ni, S.; Kirillova, I.; Fausto, N.; Blau, C. A.; Lieber, A., Dimerizer-induced proliferation of genetically modified hepatocytes. Mol Ther 2002, 5(4), 420-6. (Pubitemid 34308667)
230. Trujillo, M. E.; Pajvani, U. B.; Scherer, P. E., Apoptosis through targeted activation of caspase 8 ("ATTAC-mice"): novel mouse models of inducible and reversible tissue ablation. Cell Cycle 2005, 4(9), 1141-5. (Pubitemid 41365378)
231. Pajvani, U. B.; Trujillo, M. E.; Combs, T. P.; Iyengar, P.; Jelicks, L.; Roth, K. A.; Kitsis, R. N.; Scherer, P. E., Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005, 11(7), 797-803. (Pubitemid 41021214)
232. Landskroner-Eiger, S.; Park, J.; Israel, D.; Pollard, J. W.; Scherer, P. E., Morphogenesis of the developing mammary gland: Stage-dependent impact of adipocytes. Developmental Biology 2011, 344(2), 968-978.
233. Tsuruma, K.; Nakagawa, T.; Shirakura, H.; Hayashi, N.; Uehara, T.; Nomura, Y., Regulation of procaspase-2 by glucocorticoid modulatory element-binding protein 1 through the interaction with caspase recruitment domain. Biochem Biophys Res Commun 2004, 325(4), 1246-51. (Pubitemid 39535896)
234. Burnett, S. H.; Beus, B. J.; Avdiushko, R.; Qualls, J.; Kaplan, A. M.; Cohen, D. A., Development of peritoneal adhesions in macrophage depleted mice. J Surg Res 2006, 131(2), 296-301.
235. Burnett, S. H.; Kershen, E. J.; Zhang, J.; Zeng, L.; Straley, S. C.; Kaplan, A. M.; Cohen, D. A., Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. Journal of Leukocyte Biology 2004, 75(4), 612-623. (Pubitemid 38405652)
236. Ho, S. N.; Biggar, S. R.; Spencer, D. M.; Schreiber, S. L.; Crabtree, G. R., Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature 1996, 382(6594), 822-6. (Pubitemid 26299568)
237. Rivera, V. M., Controlling gene expression using synthetic ligands. Methods 1998, 14(4), 421-9.
238. Licitra, E. J.; Liu, J. O., A three-hybrid system for detecting small ligandprotein receptor interactions. Proc Natl Acad Sci U S A 1996, 93(23), 12817-21. (Pubitemid 26382726)
239. Althoff, E. A.; Cornish, V. W., A bacterial small-molecule three-hybrid system. Angew Chem Int Ed Engl 2002, 41(13), 2327-30. (Pubitemid 34778557)
240. Czlapinski, J. L.; Schelle, M. W.; Miller, L. W.; Laughlin, S. T.; Kohler, J. J.; Cornish, V. W.; Bertozzi, C. R., Conditional Glycosylation in Eukaryotic Cells Using a Biocompatible Chemical Inducer of Dimerization. J. Am. Chem. Soc. 2008.
241. Jullien, N.; Goddard, I.; Selmi-Ruby, S.; Fina, J. L.; Cremer, H.; Herman, J. P., Conditional transgenesis using Dimerizable Cre (DiCre). PLoS One 2007, 2(12), e1355.
242. Gray, D. C.; Mahrus, S.; Wells, J. A., Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease. Cell 2010, 142(4), 637-646.
243. Holsinger, L. J.; Spencer, D. M.; Austin, D. J.; Schreiber, S. L.; Crabtree, G. R., Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A 1995, 92(21), 9810-4.
244. Graef, I. A.; Holsinger, L. J.; Diver, S.; Schreiber, S. L.; Crabtree, G. R., Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. Embo J 1997, 16(18), 5618-28. (Pubitemid 27399854)
245. Ng, Y.; Ramm, G.; Lopez, J. A.; James, D. E., Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab 2008, 7(4), 348-56. (Pubitemid 351455217)
246. Patury, S.; Geda, P.; Dobry, C. J.; Kumar, A.; Gestwicki, J. E., Conditional nuclear import and export of yeast proteins using a chemical inducer of dimerization. Cell Biochem Biophys 2009, 53(3), 127-34.
247. Xu, T.; Johnson, C. A.; Gestwicki, J. E.; Kumar, A., Conditionally controlling nuclear trafficking in yeast by chemical-induced protein dimerization. Nat P rotoc 2010, 5(11), 1831-43.
248. Haruki, H.; Nishikawa, J.; Laemmli, U. K., The anchor-away technique: rapid, conditional establishment of yeast mutant phenotypes. Mol Cell 2008, 31(6), 925-32.
249. Mootz, H. D.; Blum, E. S.; Muir, T. W., Activation of an Autoregulated Protein Kinase by Conditional Protein Splicing. Angewandte Chemie International Edition 2004, 43(39), 5189-5192. (Pubitemid 39382538)
250. Mootz, H. D.; Muir, T. W., Protein Splicing Triggered by a Small Molecule. Journal of the American Chemical Society 2002, 124(31), 9044-9045. (Pubitemid 34847653)
251. Zhu, S.; Zhang, H.; Matunis, M. J., SUMO modification through rapamycinmediated heterodimerization reveals a dual role for Ubc9 in targeting RanGAP1 to nuclear pore complexes. Exp Cell Res 2006, 312(7), 1042-9.
252. Zimnik, S.; Gaestel, M.; Niedenthal, R., Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation. Nucleic Acids Res 2009, 37(4), e30.
253. Rollins, C. T.; Rivera, V. M.; Woolfson, D. N.; Keenan, T.; Hatada, M.; Adams, S. E.; Andrade, L. J.; Yaeger, D.; van Schravendijk, M. R.; Holt, D. A.; Gilman, M.; Clackson, T., A ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl Acad Sci U S A 2000, 97(13), 7096-101. (Pubitemid 30431423)
254. Rivera, V. M.; Wang, X.; Wardwell, S.; Courage, N. L.; Volchuk, A.; Keenan, T.; Holt, D. A.; Gilman, M.; Orci, L.; Cerasoli, F., Jr.; Rothman, J. E.; Clackson, T., Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 2000, 287(5454), 826-30. (Pubitemid 30084319)
255. Janse, D. M.; Crosas, B.; Finley, D.; Church, G. M., Localization to the proteasome is sufficient for degradation. J Biol Chem 2004, 279(20), 21415-20. (Pubitemid 38656551)
256. Pratt, M. R.; Schwartz, E. C.; Muir, T. W., Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt. Proc Natl Acad Sci U S A 2007, 104(27), 11209-14. (Pubitemid 47175120)
257. Lau, H. D.; Yaegashi, J.; Zaro, B. W.; Pratt, M. R., Precise Control of Protein Concentration in Living Cells. Angewandte Chemie International Edition 2010, 49(45), 8458-8461.
258. Stankunas, K.; Bayle, J. H.; Havranek, J. J.; Wandless, T. J.; Baker, D.; Crabtree, G. R.; Gestwicki, J. E., Rescue of Degradation-Prone Mutants of the FK506-Rapamycin Binding (FRB) Protein with Chemical Ligands. Chembiochem 2007, 8(10), 1162-9. (Pubitemid 47194824)
259. Banaszynski, L. A.; Chen, L.-c.; Maynard-Smith, L. A.; Ooi, A. G. L.; Wandless, T. J., A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules. Cell 2006, 126(5), 995-1004. (Pubitemid 44310772)
260. Grimley, J. S.; Chen, D. A.; Banaszynski, L. A.; Wandless, T. J., Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains. Bioorg Med Chem Lett 2008, 18(2), 759-61.
261. Armstrong, C. M.; Goldberg, D. E., An FKBP destabilization domain modulates protein levels in Plasmodium falciparum. Nat Methods 2007, 4(12), 1007-9. (Pubitemid 350201770)
262. Herm-Gotz, A.; Agop-Nersesian, C.; Munter, S.; Grimley, J. S.; Wandless, T. J.; Frischknecht, F.; Meissner, M., Rapid control of protein level in the apicomplexan Toxoplasma gondii. Nat Methods 2007, 4(12), 1003-5. (Pubitemid 350201768)
263. Chu, B. W.; Banaszynski, L. A.; Chen, L. C.; Wandless, T. J., Recent progress with FKBP-derived destabilizing domains. Bioorg Med Chem Lett 2008, 18(22), 5941-4.
264. Bonger, K. M.; Chen, L. C.; Liu, C. W.; Wandless, T. J., Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat Chem Biol 2011, 7(8), 531-7.
265. Marks, K. M.; Braun, P. D.; Nolan, G. P., A general approach for chemical labeling and rapid, spatially controlled protein inactivation. Proc Natl Acad Sci U S A 2004, 101(27), 9982-7. (Pubitemid 38891182)
266. Schneekloth, J. S., Jr.; Crews, C. M., Chemical approaches to controlling intracellular protein degradation. Chembiochem 2005, 6(1), 40-6. (Pubitemid 40128633)
267. Sadovski, O.; Jaikaran, A. S.; Samanta, S.; Fabian, M. R.; Dowling, R. J.; Sonenberg, N.; Woolley, G. A., A collection of caged compounds for probing roles of local translation in neurobiology. Bioorg Med Chem 2010, 18(22), 7746-52.
268. Umeda, N.; Ueno, T.; Pohlmeyer, C.; Nagano, T.; Inoue, T., A photocleavable rapamycin conjugate for spatiotemporal control of small GTPase activity. J Am Chem Soc 2011, 133(1), 12-4.
269. Karginov, A. V.; Zou, Y.; Shirvanyants, D.; Kota, P.; Dokholyan, N. V.; Young, D. D.; Hahn, K. M.; Deiters, A., Light Regulation of Protein Dimerization and Kinase Activity in Living Cells Using Photocaged Rapamycin and Engineered FKBP. J Am Chem Soc 2011.
270. Marinec, P. S.; Chen, L.; Barr, K. J.; Mutz, M. W.; Crabtree, G. R.; Gestwicki, J. E., FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. Proceedings of the National Academy of Sciences 2009, 106(5), 1336-1341.
271. Braun, P. D.; Barglow, K. T.; Lin, Y. M.; Akompong, T.; Briesewitz, R.; Ray, G. T.; Haldar, K.; Wandless, T. J., A bifunctional molecule that displays context-dependent cellular activity. J Am Chem Soc 2003, 125(25), 7575-80. (Pubitemid 36750278)
272. Sellmyer, M. A.; Stankunas, K.; Briesewitz, R.; Crabtree, G. R.; Wandless, T. J., Engineering small molecule specificity in nearly identical cellular environments. Bioorg Med Chem Lett 2007, 17(10), 2703-5. (Pubitemid 46636271)
273. Robers, M.; Pinson, P.; Leong, L.; Batchelor, R. H.; Gee, K. R.; Machleidt, T., Fluorescent labeling of proteins in living cells using the FKBP12 (F36V) tag. Cytometry A 2009, 75(3), 207-24.
274. Davis, T. L.; Walker, J. R.; Campagna-Slater, V.; Finerty, P. J.; Paramanathan, R.; Bernstein, G.; MacKenzie, F.; Tempel, W.; Ouyang, H.; Lee, W. H.; Eisenmesser, E. Z.; Dhe-Paganon, S., Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol 2010, 8(7), e1000439.
275. Blau, C. A.; Peterson, K. R.; Drachman, G.; Spencer, D. M. A proliferation switch for genetically modified cells. Proceedings of the National Academy of Sciences 1997, 94(7), 3076-3081. (Pubitemid 27157266)
276. Nör, J.; Hu, Y.; Song, W.; Spencer, D. M.; Núñez, G., Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Therapie 2002, 9(7), 444-451. (Pubitemid 34428753)
277. Romano, S.; D'Angelillo, A.; Staibano, S.; Ilardi, G.; Romano, M. F. FK506-binding protein 51 is a possible novel tumoral marker. Cell Death and Disease 2010, 1, e55.
278. Hamilton, G. S., Norman, M. H., Wu, Y.-Q., Carboxylic acids and carboxylic acid isosters of N-heterocyclic compounds, WO00/32588, 2000.
279. Cooper, M. E., Donald, D. K., Hardern, D. N., Macrocyclic compounds, US5376663, 1994.